Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients

Abstract

              <span> 
                </span><h3>Purpose</h3> 
                <p>Irinotecan (CPT-11) is used to treat advanced colorectal cancer. The drug is activated by carboxylesterases and rendered inactive by CYP3A4. Recently, the efficacy of combining CPT-11 and anti-epidermal growth factor receptor (EGFR) agents was confirmed in patients with <em>KRAS</em> wild-type metastatic colorectal cancer. Clarithromycin (CAM) is a strong CYP3A inhibitor often used to prevent rash associated with anti-EGFR therapy. The objective of this study was to evaluate the risk of increased neutropenia and diarrhea in combining CPT-11 and CAM.</p> 

              <span> 
                </span><h3>Methods</h3> 
                <p>Retrospective analyses were conducted at Osaka National Hospital (Osaka, Japan) on the records of colorectal cancer patients treated with a CPT-11-containing regimen between November 2006 and January 2014. The incidence of neutropenia and diarrhea was compared between patients who received CPT-11 and CAM and patients who received CPT-11 without CAM.</p> 

              <span> 
                </span><h3>Results</h3> 
                <p>One-hundred and twenty-eight patients were included in this study, of whom 21 were concomitantly treated with CAM and 107 were not. There was no difference in the incidence of grade 3–4 neutropenia between the CAM co-administration group (10%) and the non-CAM group (16%) [Odds ratio: 0.56 (95% confidence interval: 0.12–2.62), <em>p</em> = 0.45]. No difference in the incidence of grade 3–4 diarrhea was found between the CAM co-administration group (0%) and the non-CAM group (4%) (<em>p</em> = 0.37).</p> 

              <span> 
                </span><h3>Conclusions</h3> 
                <p>This study did not identify an increase in CPT-11 toxicity by co-administration with CAM.</p> 
              <br /><br />

http://ift.tt/2uua6AO

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s